Memorial Sloan-Kettering C. difficile Infection Patent
Summary
Memorial Sloan-Kettering Cancer Center's patent application US20260108564A1 was published April 23, 2026, disclosing methods and compositions for reducing the risk and severity of C. difficile infection. Application No. 19303846 was filed August 19, 2025, naming Eric Pamer, Charlie Buffie, and Peter McKenney as inventors. The invention is based on the discovery that a restricted fraction of gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection through the biosynthesis of secondary bile acids.
“The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Memorial Sloan-Kettering Cancer Center has obtained publication of a new patent application (US20260108564A1) covering methods and compositions for reducing C. difficile infection risk and severity. The application discloses the therapeutic use of gut microbiota including Clostridium scindens, leveraging secondary bile acid biosynthesis to confer resistance against C. difficile. The filing date was August 19, 2025, with publication occurring April 23, 2026.
Healthcare providers and pharmaceutical companies developing microbiome-based therapeutics should monitor this publication as it may represent prior art for competing research programs in the C. difficile treatment space. Biotechnology firms and researchers in this field may wish to review the specific claims and CPC classifications (A61K 35/74, A61K 38/443, C12N 9/0006) to assess potential freedom-to-operate implications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR REDUCING CLOSTRIDIUM DIFFICILE INFECTION
Application US20260108564A1 Kind: A1 Apr 23, 2026
Assignee
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors
Eric Pamer, Charlie Buffie, Peter McKenney
Abstract
The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
CPC Classifications
A61K 35/74 A61K 38/443 A61K 45/06 C12N 9/0006 C12Q 1/26 C12Y 101/01159
Filing Date
2025-08-19
Application No.
19303846
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.